title: Acidity and lipolysis by group V secreted phospholipase A(2) strongly increase the binding of apoB-100-containing lipoproteins to human aortic proteoglycans.
abstract: Local acidic areas characterize diffuse intimal thickening (DIT) and advanced atherosclerotic lesions. The role of acidity in the modification and extra- and intracellular accumulation of triglyceride-rich VLDL and IDL particles has not been studied before. Here, we examined the effects of acidic pH on the activity of recombinant human group V secreted phospholipase A(2) (sPLA(2)-V) toward small VLDL (sVLDL), IDL, and LDL, on the binding of these apoB-100-containing lipoproteins to human aortic proteoglycans, and on their uptake by human monocyte-derived macrophages. At acidic pH, the ability of sPLA(2)-V to lipolyze the apoB-100-containing lipoproteins was moderately, but significantly, increased while binding of the lipoproteins to proteoglycans increased >60-fold and sPLA(2)-V-modification further doubled the binding. Moreover, acidic pH more than doubled macrophage uptake of soluble complexes of sPLA(2)-V-LDL with aortic proteoglycans. Proteoglycan-affinity chromatography at pH 7.5 and 5.5 revealed that sVLDL, IDL, and LDL consisted of populations with different proteoglycan-binding affinities, and, surprisingly, the sVLDL fractions with the highest proteoglycan-affinity contained only low amounts of apolipoproteins E and C-III. Our results suggest that in atherosclerotic lesions with acidic extracellular pH, sPLA(2)-V is able to lipolyze sVLDL, IDL, and LDL, and increase their binding to proteoglycans. This is likely to provoke extracellular accumulation of lipids derived from these atherogenic lipoprotein particles and to increase the progression of the atherosclerotic lesions.
authors: Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. katariina.lahdesmaki@wri.fi
authors: Katariina
authors: K
authors: Lähdesmäki
authors: Katariina
authors: K
authors: Öörni
authors: Mervi
authors: M
authors: Alanne-Kinnunen
authors: Matti
authors: M
authors: Jauhiainen
authors: Eva
authors: E
authors: Hurt-Camejo
authors: Petri T
authors: PT
authors: Kovanen
mesh_terms: D000143:Acids / Q000378:metabolism*; D001011:Aorta / Q000378:metabolism* / Q000473:pathology; D053299:Apolipoprotein B-100 / Q000378:metabolism*; D053305:Apolipoprotein C-III / Q000378:metabolism; D001057:Apolipoproteins E / Q000378:metabolism; D002846:Chromatography, Affinity; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D054505:Group V Phospholipases A2 / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008066:Lipolysis; D008074:Lipoproteins / Q000378:metabolism*; D008264:Macrophages / Q000378:metabolism; D011485:Protein Binding; D011509:Proteoglycans / Q000378:metabolism*; D013379:Substrate Specificity; D014316:Tritium
chemical_list: D000143:Acids; D053299:Apolipoprotein B-100; D053305:Apolipoprotein C-III; D001057:Apolipoproteins E; D005230:Fatty Acids, Nonesterified; D008074:Lipoproteins; D011509:Proteoglycans; D014316:Tritium; D054505:Group V Phospholipases A2